Topera Medical to showcase RhythmView system at HRS annual meeting

Topera Medical today announced that its FDA-cleared RhythmView™ 3D mapping and diagnostic system will be featured in 16 scientific presentations at the 33rd Annual Scientific Sessions of the Heart Rhythm Society (HRS), May 9-12 in Boston. The presentations will provide clinicians with additional information about the electrical source of atrial arrhythmias and will also introduce information on sources that drive ventricular arrhythmias.    

"RhythmView's contribution to these presentations speaks to the expanding interest in applying this 3D mapping platform in clinical practice," said Edward Kerslake, Topera Medical's Chief Executive Officer. "RhythmView's ability to resolve rotors in ventricular arrhythmias will be reported for the first time. This represents an interesting application for RhythmView beyond the atrial rotor mapping previously reported, and is a logical extension of our platform technology. As we prepare for the commercial launch in early 2013, we are pleased to see Topera's technology taking a lead role in transforming the way electrophysiology procedures are performed."

Schedule of scientific presentations (All times are Eastern time, with events to be held at the Boston Convention Center):

Wednesday, May 9

1:45 p.m. AF Summit at the World Trade Center

Mapping Based Catheter Ablation of Rotors in Long Standing Persistent AF.

3:00 p.m. in room 160A

AB02-03 - Targeted Ablation at Sources Alone (Focal Impulse and Rotor Modulation, FIRM) Acutely Terminates or Slows Human Atrial Fibrillation.

5:45 p.m. in the Exhibit Hall

PO1-105 - Correlation of Electrogram Characteristics and Localized Sources for Human AF.

PO1-126 -Ventricular Fibrillation Rotors Are Located in Both Ventricles in Patients with and without Structural Heart Disease.

Thursday, May 10

9:30 a.m. in the Exhibit Hall

PO2-52 - Determinants of the Number of Localized Sources for Human Atrial Fibrillation.

PO2-62 - Rotors and Focal Impulses: Mechanisms to Explain Atrial Fibrillation Initiation Remote from Triggers.

PO2-116 - Physiologically-Guided Ablation Reduces Need for Conventional Ablation of Atrial Fibrillation.

PO2-149 - Percutaneous Detection of Electrical Rotors That Drive Human Ventricular Fibrillation.

1:30 p.m. in room 253A

AB14-01 - Human Atrial Fibrillation Is Initiated by Rotors or Repetitive Focal beats that are Consistent for Multiple Triggers.

2:00 p.m. in the Exhibit Hall

PO3-61 - Identification of Localized Sources for Human Atrial Fibrillation from the Surface Electrocardiogram.

PO3-150 - Increased Global Surface ECG Phase Correlation Predicts Human Ventricular Fibrillation Rotors.

2:45 p.m. in room 210C

AB03 - Success of Focal Impulse and Rotor Modulation (FIRM) for Human Atrial Fibrillation Reflects the Adequacy of Basket Recordings.

3:45 p.m. in the Exhibit Hall

MPO2-04 - Rotors and Focal Beat Sources for Human Atrial Fibrillation Migrate Within Limited Constrained Areas.

Friday, May 11

12:30 p.m. in room 158

Classifying Fractionated Electrograms in Human Atrial Fibrillation Using Monophasic Action Potentials and Activation Mapping: Evidence for Localized Drivers, Rate Acceleration, and Nonlocal Signal Etiologies.

2:00 p.m. in room 160A

AB02-03 - Targeted Ablation at Sources Alone (Focal Impulse and Rotor Modulation, FIRM) Acutely Terminates or Slows Human Atrial Fibrillation.

2:30 p.m. in room 253A

AB35-05 - Sustaining Rotors and Focal Beats for Human Atrial Fibrillation Are Unrelated to Sites of Fractionated Electrograms.    

Source:

Topera Medical

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New nasal spray form of bumetanide shows promise for heart failure treatment